Crinetics Pharmaceuticals, Inc.
CRNX
Κατάταξη σε μετοχές
#2240
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Τιμή μετοχής
$84.95
Τελευταίος συγχρονισμός: 2026-09-01
Κεφαλαιοποίηση
$9.00B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
100.12%
Χώρα
US
Εμπόριο Crinetics Pharmaceuticals, Inc. (CRNX)
Κατηγορία
Healthcare
EPS για Crinetics Pharmaceuticals, Inc. (CRNX)
EPS στις June 2026 TTM: $-5.05
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Crinetics Pharmaceuticals, Inc., το τρέχον EPS της εταιρείας (TTM) είναι $-5.05. Στο τέλος του 2023, η εταιρεία είχε EPS $-3.69, αύξηση σε σχέση με το EPS του 2022 που ήταν $-3.15.
Ιστορικό EPS της Crinetics Pharmaceuticals, Inc. από 2016 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-5.05 | 36.86% |
| 2024 | $-3.69 | 0.00% |
| 2023 | $-3.69 | 17.14% |
| 2022 | $-3.15 | 12.50% |
| 2021 | $-2.80 | 15.70% |
| 2020 | $-2.42 | 18.05% |
| 2019 | $-2.05 | -8.07% |
| 2018 | $-2.23 | 237.88% |
| 2017 | $-0.66 | 53.49% |
| 2016 | $-0.43 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $17.32 | -442.97% |
US
|
|
| $-7.98 | 58.02% |
US
|
|
| $-5.29 | 4.75% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -649.31% |
NL
|
